Laminar Pharma key facts
- Operator of a biopharmaceutical company intended to focus on the discovery of membrane-lipid therapy-based drugs.
- Laminar Pharma’s last known valuation is $168.0M.
- It has raised $46.0M; the latest was Later Stage VC ($9.7M) in Nov 2024.
- Notable investors include Keiretsu Forum, OK Ventures, Dentol Capital, Alba Pérez Foundation, Horizon 2020 — 7 tracked in total.
- Status: Privately Held (backing).
- ·Watch Laminar Pharma: the Monday email on marks, rounds and moves
Laminar Pharma funding rounds
No funding rounds for Laminar Pharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Laminar Pharma valuation
Laminar Pharma's last known valuation is $168 million. The figure stands until a priced round, a secondary trade or an institutional fund mark prices the stock again.
Laminar Pharma investors
7 investors are on record for Laminar Pharma, including Keiretsu Forum, OK Ventures, Dentol Capital and Alba Pérez Foundation.
About Laminar Pharma
Operator of a biopharmaceutical company intended to focus on the discovery of membrane-lipid therapy-based drugs. The company's drugs specifically interact with and modulate the activity of key signal-transduction peripheral proteins involved in the pathogenesis of serious diseases like cancer, inflammatory or metabolic diseases, enabling physicians with a safe and efficacious therapeutic alternative.
- Sector
- Healthcare
- HQ
- Palma de Mallorca, Spain
- Founded
- 2006
- Employees
- 30
- Website
- laminarpharma.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Laminar Pharma’s last known valuation. A PrivateMarketView mark is published once fund marks, secondary prints or a priced round let us confirm it.